Signal
Lilly warns of dangerous impurities in tirzepatide knockoff compounds
Eli Lilly has raised concerns about high levels of impurities found in compounded versions of tirzepatide, a GLP-1 receptor agonist used for obesity treatment. The company warns that these knockoff formulations, some combined with vitamin B12, may pose safety risks to patients.
rssx
clinical_trialssafety_signalsdrug_development
Evidence locked
Today's free sample is only available for the edition's flagship signal.
Evidence preview
- BioPharmaDive report on Lilly's impurity warningsbiopharmadive.com
- FiercePharma coverage of Lilly's compounding disputefiercepharma.com